Adipose-derived mesenchymal stem cell transplantation for treatment of chronic obstructive pulmonary disease

doi:10.3969/j.issn.2095-4344.2016.41.015

Abstract

Abstract:

BACKGROUND: Chronic obstructive pulmonary disease is progressive respiratory disease characterized by airflow limitation.
OBJECTIVE: To investigate the therapeutic effect of adipose-derived mesenchymal stem cell transplantation in rats with chronic obstructive pulmonary disease.
METHODS: Sixty healthy male Sprague-Dawley rats were randomly divided into control, model and treatment groups (n=20 per group). Rat models of chronic obstructive pulmonary disease were made in the model and treatment group, while no treatment was done in the control group. After modeling, rats in the treatment group were given tail vein injection of CM-Dil-labeled adipose-derived mesenchymal stem cells, and rats in the model and control groups given the same amount of normal saline. Rat pulmonary ventilation function, inflammatory factor level and pathological changes of the lung were detected at 14 days after cell transplantation.
RESULTS AND CONCLUSION: After modeling, reduced lung function was found in rats with chronic obstructive pulmonary disease, but the cell transplantation significantly improved this reduction (P < 0.05). Compared with the model group, significantly reduced indexes were visible in the treatment group (P < 0.05), including the total number of white blood cells, the number of macrophages and neutrophils, levels of interleukin-8, tumor necrosis factor α and C-reactive protein in the bronchoalveolar lavage fluid as well as serum level of malondialdehyde, while serum superoxide dismutase activity was increased significantly in the treatment group (P < 0.05). In the treatment group, emphysema-like changes were mitigated and CM-Dil-labeled adipose-derived mesenchymal stem cells were capable of homing to the lung tissue of rats with chronic obstructive pulmonary disease and survived. All these findings show that adipose-derived mesenchymal stem cell transplantation can improve lung function of rats with chronic obstructive pulmonary disease, and reduce inflammatory response, which has for certain some therapeutic effects.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Pulmonary Disease, Chronic Obstructive, Adipose Tissue, Mesenchymal Stem Cell Transplantation, Tissue Engineering

CLC Number:

R394.2

Hao Shu-an, Wu Qi, Wang Mao-jun. Adipose-derived mesenchymal stem cell transplantation for treatment of chronic obstructive pulmonary disease[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(41): 6177-6182.

Figures/Tables 1

References

[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志:电子版,2014,6(2):67-80.
[2] Vaz Fragoso CA, Gill TM. Defining chronic obstructive pulmonary disease in an aging population. J Am Geriatr Soc. 2010;58(11):2224-2226.
[3] 赵红旗,罗晓寒.无创通气治疗慢性阻塞性肺病并发II型呼吸衰竭临床观察[J].实用医院临床杂志,2010,7(2):95-97.
[4] 聂姗,王浩彦.慢性阻塞性肺疾病与系统性炎症[J].心肺血管病杂志,2011,29(6):541-543.
[5] 邱川,李明才,武燕.慢性阻塞性肺疾病气道炎症的研究进展[J].中国呼吸与危重监护杂志,2011,10(2):196-199.
[6] Cristóvão C, Cristóvão L, Nogueira F, et al. Evaluation of the oxidant and antioxidant balance in the pathogenesis of chronic obstructive pulmonary disease. Rev Port Pneumol. 2013;19(2):70-75.
[7] 余国辉,陈敏.慢性阻塞性肺疾病发病机制的发展状况[J].临床肺科杂志,2010,15(1):72-74.
[8] Lindenmair A, Hatlapatka T, Kollwig G, et al. Mesenchymal stem or stromal cells from amnion and umbilical cord tissue and their potential for clinical applications. Cells. 2012;1(4):1061-1088.
[9] 胡泽斌,王立生,崔春萍,等.干细胞临床应用安全性评估报告[J].中国医药生物技术,2013,8(5):349-361.
[10] Amable PR, Teixeira MV, Carias RB, et al. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly. Stem Cell Res Ther. 2014;5(2):53.
[11] de Girolamo L, Lucarelli E, Alessandri G, et al. Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des. 2013;19(13):2459-2473.
[12] 任薇,孙耕耘,王胜,等.阿奇霉素对慢性阻塞性肺疾病模型大鼠气道炎症和气道黏液高分泌的影响[J].中国病理生理杂志,2015,31(10):1767-1771.
[13] 任薇,王胜.低分子肝素对慢性阻塞性肺疾病急性加重期患者血栓前状态影响及临床疗效观察[J].安徽医学,2014, 35(6):734-736,737.
[14] Lu M, Yao WZ, Zhong NS, et al. Asymptomatic patients of chronic obstructive pulmonary disease in China. Chin Med J (Engl). 2010;123(12):1494-1499.
[15] Lu M, Yao W, Zhong N, et al. Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China. Respirology. 2010;15(7):1072-1078.
[16] 甘桂香,胡瑞成.吸烟慢性阻塞性肺疾病大鼠肺组织内质网相关凋亡基因Caspase-12的表达[J].中国呼吸与危重监护杂志,2011,10(1):33-35.
[17] 范秀,潘海燕.炎性递质在慢性阻塞性肺疾病气道炎症反应中的作用[J].中国医药,2012,7(11): 1485-1486.
[18] Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.
[19] Kherbeck N, Tamby MC, Bussone G, et al. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol. 2013;44(1):31-38.
[20] Martinez FJ, Donohue JF, Rennard SI. The future of chronic obstructive pulmonary disease treatment- difficulties of and barriers to drug development. Lancet. 2011;378(9795):1027-1037.
[21] 文富强,申永春.慢性阻塞性肺疾病的抗炎治疗证据和重要性[J].中国医刊,2011,46(12) : 87-90.
[22] 居朝霞,刘霞英,陆忠华.呼吸训练在慢性阻塞性肺疾病患者康复中的应用[J].中国老年学杂志,2010,30(2): 284-285.
[23] 刘前桂,李永杰,郑曦,等.6分钟步行试验在呼吸康复训练中的临床应用[J].临床肺科杂志,2010,15(1):129-131.
[24] 王亚勤,郑彩娥.应用综合康复护理措施改善老年慢性阻塞性肺疾病患者肺功能[J].中华护理杂志,2012 ,47(1): 25-27.
[25] 方晓聪,王向东,白春学.慢性阻塞性肺疾病在中国的诊治现状[J].国际呼吸杂志,2011,31(7):493-497.
[26] 高远毅.慢性阻塞性肺疾病的临床治疗观察与分析[J].当代医学,2011,17(10):9-10.
[27] Rabe KF, Wedzicha JA. Controversies in treatment of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1038-1047.
[28] de Girolamo L, Lucarelli E, Alessandri G, et al. Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des. 2013;19(13):2459-2473.
[29] Bieback K, Brinkmann I. Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy.World J Stem Cells. 2010;2(4):81-92.
[30] Kim N, Cho SG. Clinical applications of mesenchymal stem cells. Korean J Intern Med. 2013;28(4):387-402.
[31] 李建鑫,杨亮,王文良.脂肪间充质干细胞在组织工程中的应用[J].中国组织工程研究与临床康复,2010, 14(7): 1274-1277.
[32] 殷莉波,赵文秀,尹震宇,等.人脂肪间充质干细胞的分离培养及其鉴定[J].中国组织工程研究与临床康复,2010, 14(32):5997-6000.
[33] Al-Nbaheen M, Vishnubalaji R, Ali D, et al. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev. 2013;9(1):32-43.
[34] Liu AR, Liu L, Chen S, et al. Activation of canonical wnt pathway promotes differentiation of mouse bone marrow-derived MSCs into type II alveolar epithelial cells, confers resistance to oxidative stress, and promotes their migration to injured lung tissue in vitro. J Cell Physiol. 2013;228(6):1270-1283.
[35] Weiss DJ, Casaburi R, Flannery R, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(6):1590-1598.
[36] Huh JW, Kim SY, Lee JH, et al. Bone marrow cells repair cigarette smoke-induced emphysema in rats. Am J Physiol Lung Cell Mol Physiol. 2011;301(3): L255-266.
[37] Zhen G, Xue Z, Zhao J, et al. Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells. Cytotherapy. 2010;12(5):605-614.
[38] D'Agostino B, Sullo N, Siniscalco D, et al. Mesenchymal stem cell therapy for the treatment of chronic obstructive pulmonary disease. Expert Opin Biol Ther. 2010;10(5):681-687.
[39] 张超凤,区庆坚,王志红,等.骨髓间充质干细胞移植治疗大鼠慢性阻塞性肺疾病[J].心肺血管病杂志,2011,30(1): 62-66.
[40] Katsha AM, Ohkouchi S, Xin H, et al. Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther. 2011; 19(1):196-203.
[41] Ma S, Xie N, Li W, et al. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21(2): 216-225.
[42] Cuiffo BG, Karnoub AE. Mesenchymal stem cells in tumor development: emerging roles and concepts. Cell Adh Migr. 2012;6(3):220-230.